Table 4.
In-silico pathway analysis.
| in-silico identified pathways (identified proteins of Ingenuity pathway analysis listed proteins) | |
|---|---|
| human LV biopsies | |
| RIPC | cytoskeleton (30 of 228) |
| epithelial adherens junction signaling (20 of 146) | |
| eukaryotic initiation factor 2 signaling (24 of 194) | |
| integrin signaling (25 of 219) | |
| mitochondrial function (24 of 171) | |
| sham | epithelial adherens junction signaling (12 of 146) |
| melatonin (8 of 71) | |
| protein kinase A signaling (12 of 146) | |
| tight junction signaling (12 of 167) | |
| porcine LV biopsies | |
| RIPC | calcium signaling (26 of 178) |
| cytoskeleton (25 of 228) | |
| epithelial adherens junction signaling (21 of 146) | |
| mitochondrial function (18 of 171) | |
| protein kinase A signaling (35 of 392) | |
| sham | cytoskeleton (21 of 228) |
| integrin linked kinase signaling (20 of 196) | |
| mitochondrial function (17 of 171) | |
| tight junction signaling (17 of 167) |
In-silico pathway analysis was performed with all identified proteins having ≥2-fold higher expression/phosphorylation with remote ischemic preconditioning (RIPC) versus with sham in human left ventricular (LV) biopsies taken at early reperfusion after cardioplegic ischemic arrest and in porcine LV biopsies taken at early reperfusion after coronary occlusion using Ingenuity pathway analysis software.